Navigation Links
Dr. Michael Hanley Joins Celtaxsys as CEO
Date:12/2/2010

ATLANTA, Dec. 2, 2010 /PRNewswire/ -- Georgia -based drug discovery start-up, Celtaxsys, Inc. is pleased to announce that Dr. Michael Hanley has joined the company as its new Chief Executive Officer and Chairman of the Board of Directors.  Dr. Hanley has served on both the Scientific Advisory Board and Board of Directors of Celtaxsys since 2007. Dr. Hanley brings more than 20 years of managerial experience in the international life science industry including drug discovery, product development, and production.  He was most recently the Chief Scientific Officer for Amylin Pharmaceuticals where he was responsible for discovery research and preclinical development.  

"We are very pleased that Dr. Hanley has joined us as CEO," says William Reddick, CFO and Founder of Celtaxsys. "His background as an industry leader, and as an innovative drug hunter, with direct knowledge of our area of research, are qualities well-matched to our needs. We are delighted in the strengths he brings to Celtaxsys."  

"Over the last few years I have gained an insight into the innovative technology and exciting research and development that are at the core of Celtaxsys. I look forward towards building long-term, future success and stakeholder value at the Company," says Michael Hanley.  

From 1981 to 1997, Dr. Hanley held faculty positions at Imperial College, London, the Medical Research Council Laboratories, Cambridge, and the University of California at Davis, where he was Professor of Biological Chemistry. From 1997 to 2003, he was a senior consultant for healthcare investors in the venture capital and banking communities and for biotechnology companies such as Cell Therapeutics, Zymogenetics, Elan Pharmaceuticals, and Chiron. Dr. Hanley has founded several start-ups, such as Resolvyx Pharmaceuticals and Psylin Neurosciences, and is currently on boards of Aileron Therapeutics, Metabolic Solutions Development Company, Isogenica, and Pieris. He received a bachelor's degree in Biochemistry and a Ph.D. in Molecular Biology from the University of California, Berkeley.

About Celtaxsys

Celtaxsys is privately-held start-up focused on discovery and development of therapeutics to treat inflammation. The Company has identified a portfolio of immunoregulators that redirect immune cell migration and activation. Initial product candidates can ameliorate acute and chronic inflammatory disorders of cutaneous, and other, barrier epithelia.

For more information please contact Ralph Grosswald at rgrosswald@celtaxsys.com


'/>"/>
SOURCE Celtaxsys, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinsons Disease
2. Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
3. Michael J. Fox Foundation Launches Parkinsons Progression Markers Initiative (PPMI)
4. Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
5. Canadas Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing
6. Michael Garippa Joins SynCardia as President
7. 2010 Michael E. DeBakey Journalism Awards Announced
8. Michael Youssef Offers Insight into the Muslim Perspective on Oil and the World Economy
9. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
10. Michael Sitaras of SavATree Earns ISA Certified Arborist Designation
11. Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Ind. , Dec. 6, 2016 Zimmer ... "Company") today announced the pricing terms of its ... to $1.25 billion aggregate purchase price (excluding accrued and ... settlement date and excluding fees and expenses related ... the debt securities identified in the table below ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... company focused on discovery and development of precision treatments for neurodegenerative diseases, ... for Alzheimer’s disease (AD) inhibited the direct neurotoxic effect of prion-like forms ...
(Date:12/5/2016)... ... 05, 2016 , ... This composition patent, U.S. Patent No. ... The composition claims are not limited to any particular process to make or ... carbon fibers, graphene, and other materials. A continuation application, U.S. Patent App. ...
(Date:12/5/2016)... ... ... In anticipation of AxioMed’s exclusive cleanroom manufacturing facility in ... Lubinski will be traveling to Germany on December 6th. Mr. Lubinski will meet ... discuss the benefits of a viscoelastic total disc replacement. , AxioMed received its ...
Breaking Biology Technology:
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:12/2/2016)... India , December 1, 2016 ... Authentication type (Fingerprint, Voice), Future Technology (Iris Recognition ... and Region - Global Forecast to 2021", published ... USD 442.7 Million in 2016, and is projected ... at a CAGR of 14.06%.      ...
(Date:11/30/2016)...  higi SH llc (higi) announced today the ... brands, industry thought-leaders and celebrity influencers looking to ... taking steps to live healthier, more active lives. ... has built the largest self-screening health station network ... who have conducted over 185 million biometric screenings.  ...
Breaking Biology News(10 mins):